Dr. Stephanie Chambers Thomas, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 N Hospital Dr, Price, UT 84501 Phone: 435-637-4800 |
Dr. Marcos D Valdez, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 377 N Fairgrounds Rd, Price, UT 84501 Phone: 435-613-2200 |
Glenn T. Etzel, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 230 N Hospital Dr, Suite 5, Price, UT 84501 Phone: 435-637-9545 Fax: 435-637-3423 |
Dr. Bryce Kay Warr, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 317 E 100 N, Price, UT 84501 Phone: 435-637-3584 Fax: 435-637-3587 |
Dr. Travis C Engar, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 N Hospital Dr, Price, UT 84501 Phone: 435-637-4800 |
Matthew Frank Brady, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 92 N 400 E, Price, UT 84501 Phone: 435-637-6338 |
Mark A Frazier, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 300 N Hospital Dr, Price, UT 84501 Phone: 435-637-4800 |
Mr. Douglas Wilford Perkins, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 N Hospital Dr, Price, UT 84501 Phone: 435-637-4800 Fax: 435-636-4896 |
Shane D Gagon, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 377 N Fairgrounds Rd, Price, UT 84501 Phone: 435-613-2200 Fax: 435-613-2201 |
Dr. Sterling Glade Potter, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 945 W Hospital Dr, Suite # 2, Price, UT 84501 Phone: 435-637-6190 Fax: 435-637-6317 |
News Archive
Award-winning Lutherville agency, Barb Clapp Advertising & Marketing (BCAM), is pleased to announce the addition of a new client for the growing firm. BCAM will provide the LifeSpan Network, based in Columbia, MD, with public relations services.
Helicos BioSciences Corporation today announced a publication demonstrating the detection and quantification of novel small RNA molecules using Helicos' single-molecule sequencing technology. These data confirm a long-held, unproven hypothesis that mammalian cells are capable of synthesizing RNA by copying RNA molecules directly.
A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.
Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.
› Verified 9 days ago